The Ethyl Acetate Fraction of Marine Sponge *Stylissa carteri* Induces Breast Cancer Cell Death via Upregulation of Mcl-1S: an *In vitro* Study

Muhammad Hasan Bashari¹,²*, Muhammad Fadhil³,⁴, Yudhi Aulia³, Ajeng Kartika Sari³,⁵, Tenny Putri⁶, Nurul Qomarilla⁶, Harold Atmaja⁶, Ikhwán Resmala Sudji⁷, Eko Fuji Ariyanto¹, Agnes Rengga Indrati⁸, Enny Rohmawaty¹

**Abstract**

**Objective:** To evaluate the potency of the fraction of marine sponge *Stylissa carteri* in inducing cell death, inhibiting spheroid growth, and its impact on pro-apoptotic protein Mcl-1S in breast cancer cells. **Methods:** *Stylissa carteri* were collected from Pramuka Island followed by ethanol extraction and ethyl acetate fractionation. To evaluate the cytotoxic effect of fraction, the HCC-1954, MDA MB 231, and MCF-7 cells were treated with the fraction of *Stylissa carteri* and MTT assay was then performed. The effect on spheroid growth was evaluated in HCC-1954 cells. The combined effect of the ethyl acetate fraction and paclitaxel were analyzed using combination index (CI) and immunoblotting on the pro-apoptotic protein Mcl-1S. Furthermore, compounds in this fraction were identified using GC-MS. **Results:** Data showed that both the MDA MB 231 and HCC-1954 cells were interestingly more sensitive to the fraction as compared with MCF-7 cells. The IC₅₀ of the ethyl acetate fraction on HCC-1954, MDA MB 231 and MCF-7 were 4.1 µg/ml, 3.9 µg/ml, and 123.8 µg/ml, respectively. In addition, the fraction triggered spheroid destruction within 10 days. The CI of paclitaxel and ethyl acetate fraction of *Stylissa carteri* were less than 0.52. Moreover, this combination induced upregulation of the Mcl-1S protein. Furthermore, some fatty acid-based structures were predicted as the major compounds in this fraction. **Conclusion:** The ethyl acetate fraction of *Stylissa carteri* induces cell death and spheroid destruction in aggressive breast cancer cells. It has a synergistic cytotoxic effect with paclitaxel on MDA MB 231 cell death and upregulates Mcl-1S protein.

**Keywords:** Cytotoxicity- marine product- pro-apoptosis- spheroid- triple negative breast cancer

**Asian Pac J Cancer Prev, 23 (5), 1653-1660**

**Introduction**

Breast cancer (BC) is the most common cancer in women worldwide. More than 2.2 million women each year suffer from BC annually, with an estimated death rate of 684,996 in 2020 in the world (Sung, et al., 2021). Among BC subtypes, triple negative breast cancer (TNBC) and HER2-positive BC are the most aggressive types of BC and is associated with a higher mortality rate than other BC subtypes (Brewster et al., 2014; Tian et al., 2017; Johansson et al., 2019).

TNBC refers to BC type that does not overexpress the genes for the estrogen receptor (ER), progesterone receptor (PR) and receptor tyrosine-protein kinase erbB-2 (HER2) implicating that this type has no well-defined molecular targets. The cytotoxic chemotherapy is currently the only pharmacological treatment option for TNBC (Palma et al., 2015; Tian et al., 2017). One of the major cytotoxic chemotherapy in TNBC is a taxol based regimen including paclitaxel (Tian et al., 2017). Paclitaxel works by binding to the n-terminal of the tubulin subunit region, thereby increasing the stability of microtubules that are resistant to depolymerization. Paclitaxel inhibits its breakdown into tubulin, so that the cell cycle will stop at the G2/M phase and inhibit cell proliferation (Weaver, 2014; Kampan et al., 2015). Nevertheless, paclitaxel is less effective in the advance stage of TNBC.

Furthermore, HER2 is member of epidermal growth

¹Department of Biomedical Sciences, Faculty of Medicine, Universitas Padjadjaran, Indonesia. ²Oncology and Stem Cell Working Group, Faculty of Medicine, Universitas Padjadjaran, Indonesia. ³Graduate School of Biomedical Sciences Master Program, Faculty of Medicine, Universitas Padjadjaran, Bandung, Indonesia. ⁴Faculty of Medicine, Universitas Pasundan, Bandung, Indonesia. ⁵Medical Biology Department, Faculty of Medicine, Universitas Islam Bandung, Bandung, Indonesia. ⁶Laboratory of Advanced Biomedicine, Faculty of Medicine, Universitas Padjadjaran, Indonesia. ⁷Laboratory of Biomedicine, Faculty of Medicine, Universitas Andalas, Padang, Indonesia. ⁸Department of Clinical Pathology, Faculty of Medicine, Universitas Padjadjaran/ Dr. Hasan Sadikin General Hospital Bandung, Indonesia. *For Correspondence: bashari@unpad.ac.id
factor (EGFR) family whom its amplification results in activation of tyrosine kinase that initiate MAPK and PI3K/Akt signaling cascade. The signaling cascades amplified by HER2 are responsible for cell differentiation, migration, cell cycle control, angiogenesis, and apoptosis avoidance (Lee-Hoeflich et al., 2008; Loibl and Gianni, 2017; Hsu and Hung, 2018; Patel et al., 2020). Therefore, HER2 BC patients are treated with HER2 inhibitors (e.g. trastuzumab, lapatinib, pertuzumab). Unfortunately, about two third of HER2-positive BC patients are not well response to trastuzumab. Different mechanism of resistance have been identified (Patel et al., 2020).

A novel drug discovery for TNBC as well as HER2-positive BC patients is necessary to achieve better BC patient survival. One of the promising sources is from marine sponges one of which is Stylissa carteri. It is predominantly found along the Red Sea to Australia (Boohaker et al., 2012). Recent studies indicated that there are at least 15 alkaloids in Stylissa carteri (Afifi, 2017; Hamed et al., 2018). Stylissa carteri that was obtained from the island of Bangka North Sulawesi showed strong activity against HeLa cell lines and HCT-116 colon cell lines. The ethyl acetate fraction from ethanol extract Stylissa carteri was able to inhibit the activity of proteasome E2 (Ubc13) and the interactions between p53-MDM2 (E3) (Afifi, 2017). Our previous study showed the ethanol extract of Stylissa carteri has a cytotoxic effect in different BC cell lines including luminal A (MCF-7), HER2+ (SKBR3, HCC-1954) and TNBC (MDA MB 231), and also having an effect in cervical cancer cells (Hardani et al., 2018; Bashari et al., 2019). Moreover, it inhibits MDA MB 231 cell proliferation and migration (Bashari et al., 2019).

Resistence to apoptosis is one of the characteristics of TNBC as well as HER2-positive BC cells (Karagas et al., 2018; Kamalabadi-Farahani, et al., 2019). Interfering anti-apoptotic protein is one of the promising and challenging mechanisms for cancer therapy (Hassan et al., 2014). One of the proteins that play a role in the process of apoptosis is Mcl-1 (Seo et al, 2011; Wong, 2011; Elumalai et al., 2012). Myeloid cell leukemia 1 (Mcl-1) is a protein from the Bcl-2 family which plays a pivotal role as apoptotic regulator. The Mcl-1 protein has two variants namely the Mcl-1L (long) anti-apoptotic protein and the Mcl-1S (short) pro-apoptotic protein. Mcl-1S has a pro-apoptotic effect in the same way as other BH3 proteins, by binding to the anti-apoptotic Bcl-2 protein (Bae et al., 2000).

Further research on the potential of Stylissa carteri as an anti-cancer has become an opportunity to explore the combination of BC therapy. This study was aimed to determined the cytotoxic effect of a single or combination administration of ethyl acetate fraction of Stylissa carteri with paclitaxel and to determine its effect on the Mcl-1S protein expression in breast cancer cells.

Materials and Methods

Chemicals and reagents

Fetal bovine serum (FBS) (cat No. 10270106), RPMI 1640 medium (cat No. 11875093), and penicillin streptomycin (cat No. 15140122) were obtained from Gibco, USA. The primary antibodies of Mcl-1S (cat No. PA5-27597), α-tubulin primary antibody (cat No. 62204), and HRP secondary antibody (cat No. M32207) were bought from Invitrogen. Dimethyl sulfoxide (DMSO) (cat No. D8418), and 3-[4,5-dimethylthiazol-2-yl]-2,5 diphenyl tetrazolium bromide (MTT) (cat No. M2128) were purchased from Sigma-Aldrich, USA. Paclitaxel was from Pharmacy of Hasan Sadikin Hospital, Bandung, Indonesia. The other chemicals were bought from Merck, USA.

Fractionation of Stylissa carteri

Marine sponge Stylissa carteri was taken from Pramuka Island, Kepulauan Seribu National Park, Jakarta at a depth of 10 meters in 2017. The sponge was collected and identified by Mr. Beginer Subhan from Bogor Agricultural Institute. An 800 g fresh sponge was obtained and then chopped and macerated directly with ethanol before going through the extraction process. Through the extraction process 10.2 g of powder was obtained from ethanol extract. Fractionation was carried out on 5 g of extract powder using n-hexane followed by ethyl acetate as the solvent. The ethyl acetate fraction was then evaporated to obtain dry powder. They were diluted with DMSO to get a concentration of 40,000 μg/ml as the stock solution. Next, the solution was diluted with RPMI for the indicated concentrations.

Cell culture and conditions

The MCF-7, HCC-1954 and MDA MB 231 cells were used to evaluate the activity of the fraction of Stylissa carteri. MCF-7 cell are the Luminal breast cancer subtype. HCC-1954 cells are HER2 breast cancer subtype while MDA MB 231 cells are the TNBC subtype. The MDA MB 231 cells were obtained from Dr. Thordur Oskarsson (DKFZ, Germany), HCC-1954 cells were from Prof. Stefan Wiemann (DKFZ, Germany), MCF-7 cells were from Prof. Ahmad Faried and Prof. Hiroyuki Kuwano. These cell lines were cultured in RPMI 1640 medium enhanced with 10% FBS, 1% penicillin/streptomycin at 37°C with 5% CO₂.

Cytotoxicity assay

To evaluate cytotoxic activity in BC cells we used MTT assay. Cells were seeded in 96 well plate, incubated for 24 hours, treated with serial concentrations of tested materials for 72 hours. A culture medium containing 1% DMSO was used as control. Next, the cells were then given MTT solution for 4 hours. DMSO solution was added to stop the reactions and to dissolve the formazan crystal. Finally, the absorbance was recorded at 550 nm wavelength using plate reader. The assay was carried out with 3 replicates for each culture.

Spheroid growth assay

HCC-1954 spheroids were generated according to previous study (Bashari, et al., 2021). In brief, the HCC-1954 cells were seeded on agarose-coated (Sigma Aldrich, Steinheim, Germany) 96-well plates. For spheroid formation, the plates were centrifuge and incubate for 4 days. Next, spheroids were exposed or not exposed to
ethyl acetate fraction of Stylissa carteri. Spheroids were captured at day 0, 4th, 9th and 10th of intervention using camera on inverted microscope. Images were analyzed using ImageJ software to have ferret diameter.

**Combination index**

The combination index (CI) was obtained by analyzing the cytotoxic effect of different concentrations of the ethyl acetate fraction of Stylissa carteri alone or in combination with paclitaxel in MDA MB 231 cells. Combination index (CI) was generated with CompuSyn software based on Chou Talalay method (Chou, 2010).

**Western Blot**

All sample cells were washed three times with phosphate-buffered saline (PBS) and lysed. The whole cell lysates were separated by 10% SDS-PAGE followed by transferred onto super nitrocellulose membranes. The membranes were blocked with 5% nonfat milk in PBS at room temperature for 1 hour followed by incubation with the primary antibodies (Mcl-1S) (1:300) and then with horseradish peroxidase-conjugated secondary antibodies with dilution of 1: 1,000. The α-tubulin (1: 300) was used as protein loading control. The antibody-antigen binding was detected using ECL chemiluminescence and observation using film.

**GC-MS analysis**

The sample was analyzed using Shimadzu QP2010 Ultra Gas Chromatography with Mass Spectrometer as a detector. The type of MS detector was a single quadrupole (Vetvicka, and Vetvickova, 2016). A Shimadzu Reverse phase column (RP-5 non-polar column 30mm x 0.25mm x 0.25μm film thickness) was used for separation in the GC system. The MS mode was set at 70 eV ionizing energy, scanning from m/z 1 to 2,000 at 0.3 scan/sec. The temperature of the ion source and the quadrupole were set at 300°C and 280°C, while the electron multiplier voltage was set at 0.8kV. GC-grade helium (purity 99.999%) was used as carrier gas at a flow rate of 1 mL/min and separation ratio was set to 400:1. The chromatographic conditions were set as commonly used for gas chromatographic analysis. The column temperature was set at 40°C and maintained for 10 min. Then after 56 min, it was increased to 180°C (rate 2.5°C/min), and finally maintained at a rate of 20 minutes. 0.2μL was taken from the sample for Injection volume. The identification of compounds, retention time and retention index were checked with a database from NIST11 Mass Spectral Library software.

**Statistical analysis**

The five-parametric-logistic regression model by GraphPad Prism ver. 9 (GraphPad Software, LCC) was used to generate the drug curves and to determine the IC$_{50}$ values. The spheroid growth assay is for assess the growth inhibition effect. The minimal level of significance was p<0.05.

**Results**

The Ethyl Acetate Fraction of Stylissa carteri showed potent cytotoxic activity in HCC-1954 and MDA MB 231 cells, but not in MCF-7 cells

MTT assay was performed to evaluate the cytotoxic effect of the ethyl acetate fraction of Stylissa carteri in MCF-7, HCC-1954, and MDA MB 231 cells. Data revealed that the fraction of Stylissa carteri stimulated cell death in all cell lines in a dose-dependent manner (Figure 1). Interestingly, the IC$_{50}$ of the ethyl acetate fraction of Stylissa carteri showed high efficacy in HCC-1954 and MDA MB 231 cells and but not in MCF-7 cells, with an IC$_{50}$ value of 4.1 µg/ml, 3.9 µg/ml and 123.8 µg/ml, respectively. Therefore, for further study, we focused on the ethyl acetate fraction of Stylissa carteri on HCC-1954 cells and MDA MB 231 cells.

The ethyl acetate fraction of Stylissa carteri induces destruction of spheroids of HCC-1954 cells

The spheroid growth assay was conducted in HCC-1954 cells upon treatment of ethyl acetate fraction of Stylissa carteri. Interestingly, the treated spheroids

Figure 1. Cell Death Curve Showing the Percentage of MCF-7, HCC-1954 and MDA MB 231 Cells Death upon a Serial Dilution of Fractions of Stylissa Carteri. The IC$_{50}$ as well as the cell death curve were calculated and analyzed using five-parametric logistic regression.
were destroyed within 10 days of treatments (Figure 2).

The ethyl acetate fraction of *Stylissa carteri* induces synergistic cell death with paclitaxel in MDA MB 231 cells

The combination test was carried out in the same manner as the cytotoxic test using the MTT assay method, MDA MB 231 cells were exposed to a combination sample of the ethyl acetate fraction *Stylissa carteri* and paclitaxel with different concentrations. Based on the compusyn analysis, all combinations between ethyl acetate fraction *Stylissa carteri* and paclitaxel showed synergistic activity on inducing MDA MB 231 cell death (CI <1) (Figure 3).

The *Mcl-1S* Protein expression in MDA MB 231 cells upon treatment of the Ethyl Acetate Fraction of *Stylissa carteri* (SC) and paclitaxel (PTX)

*Mcl-1S* protein expression was detected using the Western blot analysis. Data showed that the ethyl acetate fraction of *Stylissa carteri* induced upregulation of Mcl-1S. Interestingly, Mcl-1S was more prominent upon combination with paclitaxel (Figure 4).

GC-MS Data of the Ethyl Acetate Fraction of *Stylissa carteri*

The results of GC-MS testing of the ethyl acetate fraction of *Stylissa carteri*, showed several peaks on the chromatogram but there were three peaks of the dominant compound (Figure 5). The three peaks were identified as compounds 2-Ethyl Hexanol, 1-Dodecanol, 9,12-Octadecadienoic acid/linoleic acid. Based on chromatogram, the ethyl acetate fraction of *Stylissa carteri* was dominated by fatty acid compounds. The other predicted compounds are shown in Table 1.

Figure 2. The Ethyl Acetate Fraction of *Stylissa carteri* Damaged Spheroid of HCC-1954 Cells in 10 Days. Spheroids were treated with 5μg/ml of ethyl acetate fraction of *Stylissa carteri* or untreated. Spheroid ferret diameter were declined upon treatment. Represented spheroids on day 10th were control (B) and treated group (C). Data was shown as mean and SD of 7 replicate each group.

Figure 3. Combination Index (CI) of the Cytotoxic Effect of the ethyl acetate Fraction of *Stylissa carteri* (SC) and Paclitaxel (PTX)

![Graph showing combination index](image)

Figure 4. Western blot analysis of Mcl-1S protein expression in MDA MB 231 cells upon treatment with ethyl acetate fraction of *Stylissa carteri* (SC) and paclitaxel (PTX)

![Western blot analysis image](image)

Figure 5. GC-MS chromatogram of ethyl acetate fraction of *Stylissa carteri* showing three dominant peaks

![GC-MS chromatogram image](image)
Table 1. GC-MS Profile of the ethyl Acetate Fraction of *Stylissa carteri*

| Compound name | Peak# | R.Time  | Area%  | Height% | A/H  |
|---------------|-------|---------|--------|---------|------|
| Ethylbenzene  | 1     | 3.001   | 0.29   | 0.75    | 7.72 |
| 1-Hexanol, 2-ethyl- | 2     | 5.248   | 1.26   | 6.43    | 3.95 |
| Benzene, 1,2,3,4-tetramethyl- | 3     | 6.641   | 0.07   | 0.24    | 6.23 |
| 1,2-Benzenediol | 4     | 7.862   | 1.5    | 2.5     | 12.08|
| 1-Undecene, 4-methyl- | 5     | 9.225   | 0.04   | 0.14    | 5.7  |
| Benzo[furan-7-carboxylic acid, 2,3-dihydro-5-b | 6     | 9.395   | 0.16   | 0.43    | 7.37 |
| Hexanoic acid, 2-ethyl-, anhydride | 7     | 10.445  | 0.02   | 0.07    | 5.21 |
| 1H-Cycloprop[e]azulene, decahydro-1,1,7-trime | 8     | 10.513  | 0.18   | 0.26    | 13.99|
| Hexadecanol | 9     | 10.745  | 0.02   | 0.13    | 3.1  |
| Azulene, 1,2,3,4,5,6,7,8-octahydro-1,4-dimethyl | 10    | 11.147  | 0.2    | 1.04    | 3.8  |
| 1-Dodecanol | 11    | 11.594  | 0.84   | 6.43    | 2.62 |
| Azulene, 1,2,3,5,6,7,8,8a-octahydro-1,4-dimeth | 12    | 12.02   | 0.43   | 1.96    | 4.44 |
| Naphthalene, 1,2,4a,5,8,8a-hexahydr | 13    | 12.195  | 0.06   | 0.25    | 4.42 |
| 1,2-Decanediol | 14    | 12.62   | 0.02   | 0.13    | 3.1  |
| Diethyl Phthalate | 15    | 12.72   | 0.02   | 0.13    | 9.85 |
| Diethyl Phthalate | 16    | 13.002  | 0.02   | 0.13    | 4.44 |
| Cyclooctasiloxane, hexadecamethyl- | 17    | 13.37   | 0.01   | 0.14    | 4.16 |
| Octacosane | 18    | 13.867  | 1.5    | 6.43    | 2.62 |
| 1-Tetradecanol | 19    | 14.043  | 0.09   | 0.16    | 10.71|
| Naphthalene, 1,6-diacetyl- | 20    | 14.595  | 0.04   | 0.16    | 4.97 |
| Hexadecane | 21    | 14.767  | 0.08   | 0.22    | 7.27 |
| Hexadecane, 1-isodecyl- | 22    | 14.981  | 0.07   | 0.13    | 11.59|
| Hexadecane | 23    | 15.389  | 0.2    | 0.72    | 5.48 |
| Isopropyl Myristate | 24    | 15.62   | 0.03   | 0.13    | 4.16 |
| Hexadecane | 25    | 15.824  | 0.03   | 0.12    | 4.75 |
| Phthalic acid, bis(7-methyloctyl) ester | 26    | 16.043  | 0.07   | 0.22    | 6.11 |
| Hexadecane, 1,1-bis(dodecyloxy)- | 27    | 16.253  | 0.2    | 0.52    | 7.59 |
| Cyclohexanone, 3-(3,3-dimethylbutyl)- | 28    | 16.397  | 0.18   | 1.03    | 3.57 |
| Hexadecanoic acid, methyl ester | 29    | 16.695  | 0.31   | 0.87    | 7.26 |
| Hexadecane, 7-methyl- | 30    | 16.845  | 0.06   | 0.15    | 8.46 |
| 1-(-)-Ascorbic acid 2,6-dihexadecanoate | 31    | 17.073  | 0.61   | 1.67    | 7.37 |
| 1-(+)-Ascorbic acid 2,6-dihexadecanoate | 32    | 17.496  | 0.66   | 1.19    | 11.22|
| D-Gulonic acid, .gamma.-lactone, cyclic 2,3,5,6- | 33    | 18.07   | 0.06   | 0.1     | 11.91|
| 9,12-Octadecadienic acid (Z,Z)-, methyl ester | 34    | 18.324  | 0.57   | 2.93    | 3.91 |
| 9,12-Octadecadienic acid (Z,Z)- | 35    | 18.746  | 0.06   | 0.1     | 11.91|
| 9,12-Octadecadien-1-ol, (Z,Z)- | 36    | 19.798  | 0.13   | 0.47    | 5.61 |
| Hexadecanoic acid, 1-((hydroxymethyl)-1,2-etha | 37    | 20.145  | 0.05   | 0.37    | 2.54 |
| Cyclononasiloxane, octadecamethyl- | 38    | 20.42   | 0.06   | 0.44    | 2.99 |
| 9,12-Octadecadienyl chloride, (Z,Z)- | 39    | 20.601  | 0.26   | 1.4     | 3.71 |
| Oleic acid, (2,2-dimethyl-1,3-dioxolan-4-yl)me | 40    | 21.796  | 0.09   | 0.2     | 9.04 |
| Ethanol, 2-(9,12-octadecadienoxy)-, (Z,Z)- | 41    | 22.303  | 0.17   | 0.21    | 16.6 |
| E-Z,1,3,12-Nonadecatriene | 42    | 23.366  | 0.28   | 0.86    | 6.65 |
| Cyclononasiloxane, octadecamethyl- | 43    | 23.52   | 0.13   | 0.63    | 4.28 |
| Tricyclo[20.8.0.0(7,16)]triacontane, 1(22),7(16)- | 44    | 25.87   | 15.12  | 4.67    | 65.19|
| Trilinolein | 45    | 26.328  | 9.25   | 5.4     | 34.53|
| 9-Octadecenoic acid (Z)-, 2-hydroxy-3-[(1-oxo | 46    | 29.964  | 38.19  | 5.44    | 141.48|
| Oxirane, hexadecyl- | 47    | 30.738  | 1.53   | 2.9     | 10.63|
| 1-Undecene, 4-methyl- | 48    | 31.97   | 7.66   | 1.95    | 79.09|
| Benzo[furan-7-carboxylic acid, 2,3-dihydro-5-b | 49    | 32.247  | 1.07   | 1.66    | 13.01|
| Hexanoic acid, 2-ethyl-, anhydride | 50    | 32.52   | 1.31   | 1.01    | 26.1 |
| Propyleneglycol monol | 51    | 33.916  | 0.27   | 0.28    | 19.56|
| Tricyclo[20.8.0.0(7,16)]triacontane, 1(22),7(16)- | 52    | 34.296  | 0.72   | 2.27    | 6.4  |
Discussion

*Stylissa carteri* is a sea sponge located spread across the Red Sea to Australia including Indonesia (Boohaker et al., 2012). There have been several studies regarding *Stylissa carteri* as an anti-cancer. Our previous study showed the ethanol extract of *Stylissa carteri* has a cytotoxic effect in different BC cell lines including luminal A (MCF-7), HER2+ (SKBR3, HCC-1954) and TNBC (MDA MB 231), and also having an effect in cervical cancer cells (Hardani, et al., 2018; Bashari, et al., 2019). Moreover, it inhibits MDA MB 231 cell proliferation and migration (Bashari, et al., 2019).

Studies showed that *Stylissa carteri* contains several compounds including alkaloids, flavonoids, triterpenoids, steroids and peptides (Afifi, 2017; Dewi, 2017). Our GC-MS chromatogram result showed ethyl acetate fraction of *Stylissa carteri* is dominated by fatty acid compounds. The three peaks were identified as compounds 2-Ethyl Hexanol, 1-Dodecanol, 9,12-Octadecadienoic acid/linoleic acid (Figure 5).

This is supported by other study that successfully isolated several compounds from *Stylissa carteri*, including Stylissamide A, Stylissoside A, and 9,10,11-Trihydroxy-(12Z)-12-Octadecenoic acid/linoleic acid (Figure 5).

![Figure 4. Upregulation of Mcl-1S Protein Upon Treatment with Combination of the ethyl Acetate Fraction of Stylissa carteri and Paclitaxel. Tubulin was used as loading control.](image)

![Figure 5. GC-MS Chromatogram of the ethyl Acetate Fraction of Stylissa carteri](image)
Stylissa carteri sponge in breast cancer cells. In this study, a small IC₅₀ values obtained from the ethyl acetate fraction of Stylissa carteri exposed to HCC-1954 and MDA MB 231 were 4.1 µg/ml and 3.9 µg/ml, respectively. Moreover, a big IC₅₀ values obtained from the ethyl acetate fraction of Stylissa carteri exposed to MCF-7 were 123.8 µg/ml (Figure 1). It is indicating that the ethyl acetate fraction of Stylissa carteri has potential activity on the aggressive cells HER2 and TNBC subtype. A compound can be categorized as a potential cytotoxic compound if the IC50 value is smaller than 20 µg/ml (Sajjadi, et al., 2015). Nevertheless, further study needs to confirm the specific effect using other cell line including the normal cell line.

Other studies showed that the alkaloid compounds contained in Stylissa carteri become protein kinase inhibitors that play a role in cell proliferation (Patel, et al., 2010). The ethanol extract of Stylissa carteri inhibits cell proliferation and induces apoptosis in TNBC cells cultured in three-dimensional cells (Bashari, et al., 2019). Similarly, the ethyl acetate fraction of Stylissa carteri triggered destruction of spheroid of HCC-1954 cells within 10 days (Figure 2).

It has been known that cancer cells activate several pathways to avoid cell death. Therefore, it is rational to target cancer cells by combining different agents which have different mechanisms. Previous studies had shown the synergistic effect of combination of ethanol extract of Stylissa carteri and paclitaxel in triggering MDA MB 231 cell death (Bashari, et al., 2019). Similarly, in this study, the ethyl acetate fraction of Stylissa carteri was combined with paclitaxel. Paclitaxel is one of the main regimens in the treatment of breast cancer. Paclitaxel works in the G2-M phase, causing cells to stop at that phase and inhibit cancer cell proliferation (Weaver, 2014; Liu, et al., 2015). Our study revealed that the combination between the ethyl acetate fraction of Stylissa carteri and paclitaxel in MDA MB 231 cells has synergistic effect on cytotoxicity of MDA MB 231 cells (Figure 3).

Furthermore, previous study showed that the isolated compound from Stylissa carteri inhibit the activity of ubiquitin-proteasomes (Ubc13) in cancer cells (Afifi, 2017). Proteasome is a protein complex that is responsible for intracellular protein degradation. The ubiquitin-proteasome (UPS) system controls almost all basic cellular processes such as cell cycle development, signal transduction and cell death (Tanaka, 2009; Afifi, 2017). One of the important substances of ubiquitin-proteasomes is p53. If p53 were accumulated under inhibition of ubiquitin-proteasomes, the activity of p53 will be increased, thus anti-cancer effects are provided. If p53 is active, its role as a tumor suppressor gene can read the damage signal from within the cell so that it will activate the apoptotic pathway intrinsically (Orlowski, 1999; Thomas et al., 2010).

Peptides contained in Stylissa carteri play a role in the regulation of pro-apoptotic proteins such as BAX and BAK. Increased expression of pro-apoptotic proteins induces apoptosis or cell death (Patel et al., 2010). Interestingly, in this study it showed the ethyl acetate fraction of Stylissa carteri induced upregulation of Mcl-1S. Moreover, Mcl-1S was more prominent upon combination with paclitaxel (Figure 4). Mcl-1S is a pro-apoptotic protein (Bae et al., 2000; Kim and Bae, 2013). Other study showed that Mcl-1S inhibit mitotic phase and cause DNA damage accumulation (Streletskaia et al., 2020).

In conclusion, the ethyl acetate fraction of Stylissa carteri has a cytotoxic effect on the aggressive BC cells, MDA MB 231 and HCC-1954 cell death. The combination of paclitaxel and ethyl acetate fraction of Stylissa carteri has a synergistic effect in inducing death of MDA MB 231 cells. The ethyl acetate fraction of Stylissa carteri and paclitaxel cause an increase in the Mcl-1S protein in MDA MB 231 cells, suggesting activation of apoptosis as the underlying mechanism. Further studies need to be conducted to identify which of the compound play important role for the finding. Knowing the ethyl acetate fraction of Stylissa carteri has a potent cytotoxic effect on the aggressive BC cells, indicating that the active compound interfere similar target in both cell types.

Author Contribution Statement

The authors confirm contribution to the paper as follows: study conception and design: Muhammad Hasan Bashari, Eko Fuji Ariyanto; data collection: Yudhi Aulia, Ajeng Kartika Sari, Tenny Putri, Nurul Qomarilla, Harold Atmaja; analysis and interpretation of results: Muhammad Hasan Bashari, Ilkwan Resmala Sudji; draft manuscript preparation: Muhammad Fadhil, Agnes Rengga Indrati, Enny Rohmawaty, Eko Fuji Ariyanto. All authors reviewed the results and approved the final version of the manuscript.

Acknowledgments

We thank Mr. Beginer Subhan from Bogor Agricultural University for collecting samples; Taman Nasional Kepulauan Seribu, Jakarta and Mrs. Pratiwi, Apt. from Dr. Hasan Sadikin Hospital, Bandung, who supported this study. This OCEAN project is supported by Universitas Padjadjaran Research Grant for MHB (1427/UN6.3.1/LT/2020) and Ministry of Research and Technology/National Research and Innovation for MHB (No. 1207/UN6.3.1/PT.00/2020) and Ministry of Research and Technology/National Research and Innovation for MHB (No. 1207/UN6.3.1/PT.00/2021). This study was carried out with the support of the infrastructure provided by Universitas Padjadjaran. The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. This study did not use any primary cells and has no ethical issues.

Statement conflict of Interest

No potential conflict of interest was reported by the authors.

References

Abdelhameed RFA, Habib ES, Eltahawy NA, et al. (2020). New cytotoxic natural products from the red sea sponge stylissa carteri. Mar Drugs, 18, 1–13.

Afifi AH (2017). The Development of New Anticancer Agents,
Which inhibit the Ubiquitin-Proteasome system from Marine Organisms. CU Theses, pp 1–16.

Bae J, Leo CP, Sheau Yu Hsu, Hsueh AJW (2000). MCL-1S, a splicing variant of the antiapoptotic BCL-2 family member MCL-1, encodes a proapoptotic protein possessing only the BH3 domain. J Biol Chem, 275, 25255–61.

Bashari MH, Arsydilluhuda FZ, Ithmsyah R, et al (2021). The Ethanol Extract of Marine Sponge Aaptos suberitoides Suppress Cell Viability, Cell Proliferation and Cell Migration in HER2-Positive Breast Cancer Cell Line. Asian Pac J Cancer Prev, 22, 25–32.

Bashari MH, Huda F, Tartila TS, et al (2019). Bioactive compounds in the ethanol extract of marine sponge Styliella carteri demonstrates potential anti-cancer activity in breast cancer cells. Asian Pac J Cancer Prev, 20, 1199–1206.

Brewster AM, Chavez-MacGregor M, Brown P (2014). Epidemiology, biology, and treatment of triple-negative breast cancer in women of African ancestry. Lancet Oncol, 15, 625–34.

Chou T-C (2010). Drug Combination Studies and Their Synergy Quantification Using the Chou-Talalay Method. Cancer Res, 70, 440–6.

Dewi AS (2017). When East meets West: the chemistry of Indonesian sponges and Australian nudibranchs. The University of Queensland.

Elumalai P, Gunadhari RN, Senthilkumar K, et al (2012). Indole alkaloids from Stylissa carteri in human breast cancer cells by nimbolide through extrinsic and intrinsic pathway. Toxicol Lett, 215, 131–42.

Hamed ANE, Schmitz R, Bergermann A, et al (2018). Bioactive pyrrole alkaloids isolated from the Red Sea: marine sponge Styliella carteri. Zeitschrift für Naturforsch C, 73, 199–210.

Hardani IN, Damara FA, Nugrahani AD, Bashari MH (2018). Ethanol extract of Styliella carteri induces cell death in parental and paclitaxel-resistant cervical cancer cells. Int J Integr Heal Sci, 6, 91–6.

Hassan M, Watari H, AbuAlmaaty A, et al. (2014). Apoptosis and Molecular Targeting Therapy in Cancer. Biomed Res Int, 2014, 1–23.

Hsu JL, Hung M-C (2018). Mechanisms of Action and Resistance of Trastuzumab in Breast Cancer.

J. Boohaker R, W. Lee M, Vishnubhotla P, et al (2012). The Use of Therapeutic Peptides to Target and to Kill Cancer Cells. Curr Med Chem, 19, 3794–3804.

Johansson ALV, Trewin CB, Hjerkind KV, et al (2019). Breast cancer-specific survival by clinical subtype after 7 years follow-up of young and elderly women in a nationwide cohort. Int J Cancer, 2019.

Kamalabadi-Farahani M, Najafabadi MRH, Jabbarpour Z (2019). Apoptotic resistance of metastatic tumor cells in triple negative breast cancer: Roles of death receptor-5. Asian Pac J Cancer Prev, 20, 1743–8.

Kampan NC, Madondo MT, McNally OM, et al (2015). Paclitaxel and its evolving role in the management of ovarian cancer. Biomed Res Int, 2015.

Karakas B, Ozmay Y, Basaga H, et al (2018). Distinct apoptotic blocks mediate resistance to panHER inhibitors in HER2+ breast cancer cells. Biochim Biophys Acta - Mol Cell Res.,

Kim JH, Bae J (2013). MCL-1ES induces MCL-1L-dependent BAX- And BAK-independent mitochondrial apoptosis. PLoS One, 2013.

Lee-Hoeflich ST, Crocker L, Yao E, et al (2008). A central role for HER3 in HER2-amplified breast cancer: Implications for targeted therapy. Cancer Res, 2008.

Liu J, Beckman BS, Foroozesh M (2013). A review of ceramide analogs as potential anticancer agents. Future Med Chem, 5, 1405–21.

Liu X, Tang H, Chen J, et al (2015). MicroRNA-101 inhibits cell progression and increases paclitaxel sensitivity by suppressing MCL-1 expression in human triple negative breast cancer. Oncotarget, 6, 20070–83.

Loibl S, Gianni L (2017). HER2-positive breast cancer. Lancet., Orlovski RZ (1999). The role of the ubiquitin-proteasome pathway in apoptosis. Cell Death Differ, 6, 303–13.

Palma G, Frasci C, Chirico A, et al (2015). Triple negative breast cancer: Looking for the missing link between biology and treatments. Oncotarget, 6, 26560–74.

Patel K, Laville R, Martin MT, et al (2010). Unprecedented stylissazoles A-C from sty lissa carteri: Another dimension for marine pyrrole-2-aminoimidazole metabolite diversity. Angew Chemie - Int Ed, 49, 4775–9.

Patel A, Unni N, Peng Y (2020). The changing paradigm for the treatment of HER2-positive breast cancer. Cancers (Basel), 2020.

Sajjadi SE, Ghanadian M, Haghjighi M, Mouhebat L (2015). Cytotoxic effect of Cousinia verbascifolia Bunge against OVCAR-3 and HT-29 cancer cells. J HerbMed Pharmacol, 4, 15–9.

Seo HS, Choi HS, Choi HS, et al (2011). Phytoestrogens induce apoptosis via extrinsic pathway, inhibiting nuclear factor-xB signaling in HER2-overexpressing breast cancer cells. Anticancer Res, 31, 3301–13.

Streletskaya AY, Senichkin VV, Prikazchikova TA, et al (2020). Upregulation of Mcl-1S Causes Cell-Cycle Perturbations and DNA Damage Accumulation. Front Cell Dev Biol, 8, 925.

Sung H, Ferlay J, Siegel RL, et al (2021). Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin, 2021.

Tanaka K (2009). The protosomae: Overview of structure and functions. Proc Japan Acad Ser B Phys Biol Sci, 85, 12–36.

Thomas LW, Lam C, Edwards SW (2010). Mcl-1; the molecular regulation of protein function. FEBS Lett, 584, 2981–9.

Tian Q, Du P, Li S, et al (2017). Effect of antitumor treatments on triple-negative breast cancer patients: A PRISMA-compliant network meta-analysis of randomized controlled trials. Medicine (Baltimore), 96, e3839.

Vetvicka V, Vetvickova J (2016). Essential Oils from Thyme (Thymus vulgaris): Chemical Composition and Biological Effects in Mouse Model. J Med Food, 19, 1180–7.

Weaver BA (2014). How Taxol/paclitaxel kills cancer cells. Mol Biol Cell, 25, 2677–81.

Wong RS (2011). Apoptosis in cancer: from pathogenesis to treatment. J Exp Clin Cancer Res, 30, 1–14.

This work is licensed under a Creative Commons Attribution-Non Commercial 4.0 International License.